Dispensing Study to Assess the Visual Performance of Optimised Prototype Contact Lenses

Inclusion Criteria: * Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent. * Be at least 18 years old, male or female. * Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator. * Have ocular health findings considered to be "normal" and which would not prevent the participant from safely wearing contact lenses. * Is correctable to at least 6/12 (20/40) or better in each eye with contact lenses. * Be suitable and willing to wear contact lenses. Exclusion Criteria: * Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses. * Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants. * Use of or a need for concurrent category S3 and above ocular medication at enrolment. Ocular medication can be prescribed during the course of the trial as per standard optometric practice. * Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial. Note: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used. * Eye surgery within 12 weeks immediately prior to enrolment for this trial. * Previous corneal refractive surgery. * Contraindications to contact lens wear. * Known allergy or intolerance to ingredients in any of the clinical trial products.